4//SEC Filing
HealthCap VII, L.P. 4
Accession 0000899243-20-018256
CIK 0001805890other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:02 PM ET
Size
16.9 KB
Accession
0000899243-20-018256
Insider Transaction Report
Form 4
HealthCap VII, L.P.
10% Owner
Transactions
- Conversion
Common Shares
2020-06-30+2,497,345→ 2,497,345 total(indirect: See Footnote) - Purchase
Common Shares
2020-06-30$17.00/sh+240,000$4,080,000→ 3,807,247 total(indirect: See Footnote) - Conversion
Common Shares
2020-06-30+1,069,902→ 3,567,247 total(indirect: See Footnote) - Conversion
Class A Preferred Exchangeable Shares
2020-06-30−13,333,333→ 0 total(indirect: See Footnote)→ Common Shares (2,497,345 underlying) - Conversion
Class B Preferred Exchangeable Shares
2020-06-30−5,712,216→ 0 total(indirect: See Footnote)→ Common Shares (1,069,902 underlying)
HealthCap VII GP S.A.
10% Owner
Transactions
- Conversion
Common Shares
2020-06-30+1,069,902→ 3,567,247 total(indirect: See Footnote) - Conversion
Class A Preferred Exchangeable Shares
2020-06-30−13,333,333→ 0 total(indirect: See Footnote)→ Common Shares (2,497,345 underlying) - Conversion
Common Shares
2020-06-30+2,497,345→ 2,497,345 total(indirect: See Footnote) - Purchase
Common Shares
2020-06-30$17.00/sh+240,000$4,080,000→ 3,807,247 total(indirect: See Footnote) - Conversion
Class B Preferred Exchangeable Shares
2020-06-30−5,712,216→ 0 total(indirect: See Footnote)→ Common Shares (1,069,902 underlying)
Footnotes (3)
- [F1]Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis.
- [F2]The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F3]Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001645161
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:02 PM ET
- Size
- 16.9 KB